Key result
Synchronized stimulation identifies ectopy-triggering ganglionated plexuses with 100% reproducibility for targeted AF ablation.
Why the study?
It was unknown whether ectopy-triggering ganglionated plexus (ET-GP) localisation is reproducible between different stimulators and if ET-GP can be mapped and ablated in persistent atrial fibrillation.
May support targeted GP ablation in persistent AF; hypothesis-generating from two patients and requires larger trials before practice change.
BACKGROUND: Ablation of autonomic ectopy-triggering ganglionated plexuses (ET-GP) has been used to treat paroxysmal atrial fibrillation (AF). It is not known if ET-GP localisation is reproducible between different stimulators or whether ET-GP can be mapped and ablated in persistent AF. We tested the reproducibility of the left atrial ET-GP location using different high-frequency high-output stimulators in AF. In addition, we tested the feasibility of identifying ET-GP locations in persistent atrial fibrillation. METHODS: Nine patients undergoing clinically-indicated paroxysmal AF ablation received pacing-synchronised high-frequency stimulation (HFS), delivered in SR during the left atrial refractory period, to compare ET-GP localisation between a custom-built current-controlled stimulator (Tau20) and a voltage-controlled stimulator (Grass S88, SIU5). Two patients with persistent AF underwent cardioversion, left atrial ET-GP mapping with the Tau20 and ablation (Precision™, Tacticath™ [n = 1] or Carto™, SmartTouch™ [n = 1]). Pulmonary vein isolation (PVI) was not performed. Efficacy of ablation at ET-GP sites alone without PVI was assessed at 1 year. RESULTS: The mean output to identify ET-GP was 34 mA (n = 5). Reproducibility of response to synchronised HFS was 100% (Tau20 vs Grass S88; [n = 16] [kappa = 1, SE = 0.00, 95% CI 1 to 1)][Tau20 v Tau20; [n = 13] [kappa = 1, SE = 0, 95% CI 1 to 1]). Two patients with persistent AF had 10 and 7 ET-GP sites identified requiring 6 and 3 min of radiofrequency ablation respectively to abolish ET-GP response. Both patients were free from AF for > 365 days without anti-arrhythmics. CONCLUSIONS: ET-GP sites are identified at the same location by different stimulators. ET-GP ablation alone was able to prevent AF recurrence in persistent AF, and further studies would be warranted.
No takes yet. Share an insight, caveat, or question.
Coyle et al. (2023) studied Atrial fibrillation (n=11). High-frequency stimulation mapping and ablation of ectopy-triggering ganglionated plexuses vs. Grass S88 stimulator was evaluated on Reproducibility of response to synchronized high-frequency stimulation (Tau20 vs Grass S88) (kappa = 1, 95% CI 1 to 1). Ectopy-triggering ganglionated plexus sites were identified with 100% reproducibility between stimulators, and targeted ablation alone prevented AF recurrence at 1 year in two persistent AF patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: